The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | An overview of trials in progress in AL amyloidosis: highlights from ISA 2024
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, gives an overview of exciting trials in progress in the field of light chain (AL) amyloidosis, including a Phase I trial evaluating venetoclax, ixazomib and dexamethasone in patients with relapsed/refractory (R/R) disease harboring t(11;14). The second trial is exploring a novel anti-BCMA bispecific antibody, ABBV-383, in the R/R setting, and the final study highlighted by Dr Sanchorawala is evaluating the role of stem cell transplantation (SCT) in patients with newly diagnosed disease. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Support/P.I. Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion
Consultant Pfizer, Janssen, Attralus, GateBio, Abbvie
Scientific Advisory Board Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, Nexcella
